Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer

Oncogenesis

Volumn 3, Issue , 2014, Pages

  Ghasemi, R ^a,b   Rapposelli, I G ^a   Capone, E ^a   Rossi, C ^c   Lattanzio, R ^a   Piantelli, M ^a,d   Sala, G ^a,d   Iacobelli, S ^d  

^a UNIVERSITY OF CHIETI   (Italy)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Center of Excellence on Aging (CeSI)   (Italy)

^d MediaPharma Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; EV20; K RAS PROTEIN; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; NEU DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; IMMUNOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEDICATION COMPLIANCE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; CELL PROLIFERATION ASSAY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84907323210     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.31     Document Type: Article

References (30)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29
2. Hidalgo M. Pancreatic cancer. New Engl J Med 2010; 362: 1605-1617
3. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009; 6: 412-422
4. Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW, Korc M. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995; 1: 1413-1420
5. Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007; 13: 3356-3362
6. Saxby AJ, Nielsen A, Scarlett CJ, Clarkson A, Morey A, Gill A et al. Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 2005; 29: 1125-1134
7. Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y et al. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 2003; 11: 305-309
8. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004; 22: 706-712
9. Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610
10. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966
11. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 2010; 316: 1083-1100
12. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS. The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 2004; 91: 1190-1194
13. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-509
14. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012; 12: 553-563
15. Liles JS, Arnoletti JP, Kossenkov AV, Mikhaylina A, Frost AR, Kulesza P et al. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. Br J Cancer 2011; 105: 523-533
16. Frolov A, Schuller K, Tzeng CW, Cannon EE, Ku BC, Howard JH et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 2007; 6: 548-554
17. Liles JS, Arnoletti JP, Tzeng CW, Howard JH, Kossenkov AV, Kulesza P et al. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther 2010; 10: 555-563
18. Kolb A, Kleeff J, Arnold N, Giese NA, Giese T, Korc M et al. Expression and differential signaling of heregulins in pancreatic cancer cells. Int J Cancer 2007; 120: 514-523
19. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 2010; 107: 7692-7697
20. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 1995; 10: 1813-1821
21. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003; 284: 54-65
22. Sala G, Traini S, D'Egidio M, Vianale G, Rossi C, Piccolo E et al. An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene 2012; 31: 1275-1286
23. Sala G, Rapposelli IG, Ghasemi R, Piccolo E, Traini S, Capone E et al. EV20, a novel Anti-ErbB-3 humanized antibody, promotes ErbB-3 down-regulation and inhibits tumor growth in vivo. Transl Oncol 2013; 6: 676-684
24. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al. Adjuvant trastuzumab in HER2-positive breast cancer. New Engl J Med 2011; 365: 1273-1283
25. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
26. Carraway KL, Soltoff SP, Diamonti AJ, Cantley LC. Heregulin Stimulates Mitogenesis and Phosphatidylinositol 3-Kinase in Mouse Fibroblasts Transfected with erbB2/neu and erbB3. J Biol Chem 1995; 270: 7111-7116
27. Lemmon MA. Ligand-induced ErbB receptor dimerization. Exp Cell Res 2009; 315: 638-648
28. Buck E, Eyzaguirre A, Haley JD, Gibson NW, Cagnoni P, Iwata KK. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 2006; 5: 2051-2059
29. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-475
30. Lee Y, Ma J, Lyu H, Huang J, Kim A, Liu B. Role of erbB3 receptors in cancer therapeutic resistance. Acta Biochim Biophys Sin (Shanghai) 2014; 46: 190-198